This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

57/100

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Inflammation and the immune system

Topic: Risk, prevention and care in population studies

Recent studies have also shown that cannabinoids may have more specific effects in interrupting the pathological process in Alzheimer's disease. Main results Only one study met the inclusion criteria. The data in the study report were presented in such a way that they could not be extracted for further analysis and there was insufficient quantitative data to validate the results.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Krishnan, S., Cairns, R., & Howard, R. (2009). Cannabinoids for the treatment of dementia. The Cochrane database of systematic reviews. https://doi.org/10.1002/14651858.cd007204.pub2

Vancouver

Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. The Cochrane database of systematic reviews. 2009. doi:10.1002/14651858.cd007204.pub2. PMID: 19370677.

BibTeX

@article{krishnan2009-19370677,
  author  = {Krishnan, S. and Cairns, R. and Howard, R.},
  title   = {{Cannabinoids for the treatment of dementia}},
  journal = {The Cochrane database of systematic reviews},
  year    = {2009},
  doi     = {10.1002/14651858.cd007204.pub2},
  pmid    = {19370677},
  url     = {https://doi.org/10.1002/14651858.cd007204.pub2}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Recent studies have also shown that cannabinoids may have more specific effects in interrupting the pathological process in Alzheimer's disease.
Main results Only one study met the inclusion criteria.
The data in the study report were presented in such a way that they could not be extracted for further analysis and there was insufficient quantitative data to validate the results.

Why it matters

This systematic review searched for trials of cannabinoids to treat dementia but found only one study that met its criteria, and that study's data could not be extracted for analysis. With insufficient quantitative data to validate the results, the review offers no reliable evidence on whether cannabinoids help people with dementia.

Study details

Study designsystematic review
Evidence strengthHigh

How this study scored 57/100

Published in a leading specialty journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (The Cochrane database of systematic reviews)
Journal's citation record	3 / 4	Cochrane Database of Systematic Reviews: journal h-index 468 (OpenAlex, 2026-10-29)
Study design	12 / 12	A systematic review of all the studies on the question
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2009 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	A review of other studies — randomisation is not credited here
Times cited	4 / 7	Cited 88 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	4.6 citations a year over 19 year(s) since 2009
Impact for its field and year	3 / 6	Cited 3.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 3 other studies in this library
Still being cited	1 / 4	Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Robert Howard: h-index 95 (OpenAlex, whole career)
Institution's track record	0 / 3	Maudsley Hospital: institution h-index 277 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 19370677)
Free to read	0 / 2	Behind a paywall — scores zero
Total	57 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Inflammation and the immune system

Also tagged “placebo-controlled”

783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →